简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2014-12-25 15:22 PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations
2014-12-22 16:09 'nano tech 2015' :One of the World's Largest Integrated Nanotechnology Exhibitions Upcoming
2014-12-18 17:33 LFB S.A. Announces Achievement of Patient Enrollment Target for PerSept 1 Program for the Evaluation of Recombinant Factor Seven Efficacy by Prospective Clinical Trials
2014-12-18 17:24 New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke Patients
2014-12-18 11:59 Ossianix Expands and Extends Its Research Collaboration with Lundbeck on CNS Therapeutics
2014-12-15 17:24 Terumo BCT Congratulates Two Recipients of 2014 Advancing Apheresis Awards
2014-12-12 18:16 Nestlé Skin Health to Open Global Network of Innovation Hubs to Advance Next Generation of Skin Health
2014-12-12 17:02 MP Biomedicals Receives First Ever FDA Approval for HTLV Confirmatory Assay
2014-12-12 10:12 Wolters Kluwer Health Introduces UpToDate Anywhere Mobile Clinical Decision Support in Asia
2014-12-10 12:29 Quintiles Named 2014 Frost & Sullivan Asia-Pacific CRO of the Year
2014-12-10 12:07 Cegedim Relationship Management Partners with Aktana to Empower Commercial Teams with an Out-of-the-Box and Intuitive Decision Support Engine via Mobile Intelligence CRM
2014-12-10 10:00 A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas
2014-12-09 18:03 Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
2014-12-09 17:42 Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
2014-12-09 17:00 Otsuka Pharmaceutical to Acquire Avanir Pharmaceuticals
2014-12-09 14:57 Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
2014-12-09 14:33 Acelity Appoints Gaurav S. Agarwal as Group President, Businesses and Innovation
2014-12-08 17:07 Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
2014-12-05 12:19 Quintiles Named Best Contract Research Organization at SCRIP Awards for Third Consecutive Year
2014-12-02 15:38 Takeda’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis

Business Wire Weibo

Press Releases

Latest Releases